Recent studies suggest that immunologic targeting of melanoma is a promising therapeutic strategy 1,2 . A key role for CD4 + T cells in tumor immunity has emerged from several studies using mouse models [3] [4] [5] [6] . Adoptive transfer of tumor-specific CD4 + T cells has been shown to eradicate large established and metastatic melanomas in mice [5] [6] [7] . The role of T H 17 cells in tumor immunity is, however, not clear, with apparently contradictory results having been published [8] [9] [10] [11] [12] [13] . ROR-γt, an isoform of ROR-γ, is a lineage-specific transcription factor that is crucial for the development of T H 17 cells [14] [15] [16] and whose deficiency abrogates the development of IL-17A-secreting T H 17 cells. High expression of ROR-γ is reported in autoimmune and inflammatory diseases 14, 17 . We explored a distinct approach to studying the role of T H 17 cells in tumor immunity using mice whose T cells were deficient in this transcription factor. Using ROR-γ-deficient mice (Rorc −/− mice), we observed marked growth inhibition of subcutaneous B16F10 melanomas compared to WT mice. Transcriptional profiling experiments using purified CD4 + T cells differentiated under T H 17 polarizing conditions revealed strikingly high expression of IL-9 in ROR-γ − CD4 + T cells compared with ROR-γ + CD4 + T cells. We therefore explored a putative role of IL-9 in antitumor immunity, and found marked tumor growth inhibition mediated by IL-9 and T H 9 cells. In addition, we found T H 9 cells in healthy human skin and blood, as well as in metastatic lesions of subjects with advanced melanoma. We have here identified new and previously unreported roles of IL-9 and T H 9 cells in tumor immunity in mice.
control mice (Fig. 1d) . There was no difference in the number of melanoma-tumorinfiltrating CD4 + CD25 + , forkhead box P3 (FoxP3) + T cells (T regulatory cells) between the Rorc +/+ ch (7.2% ± 0.4% (mean ± s.e.m.) and the Rorc −/− ch mice (5.9% ± 0.7%).
High IL-9 expression in ROR-g − T cells
To further explore the mechanism of melanoma growth inhibition in Rorc −/− ch mice, we performed transcriptional profiling analyses using CD4 + T cells from Rorc −/− and Rorc +/+ mice differentiated under T H 17 polarizing conditions. The expression of IL-17A, IL-17F and IL-23R was much lower in the ROR-γ − CD4 + T cells than in the ROR-γ + CD4 + T cells (Fig. 2) . However, expression of IL-9 in the ROR-γ − CD4 + T cells was markedly higher than in the ROR-γ + CD4 + T cells ( Fig. 2 and Supplementary Fig. 2 ). The expression levels of granzyme-B and granzyme-C were also markedly elevated in ROR-γ − CD4 + T cells compared to ROR-γ + CD4 + T cells. Because of the substantial upregulation of IL-9 under these conditions, we focused our subsequent experiments on the potential role of IL-9 in tumor immunity.
To determine whether the T cells from the Rorc −/− mice had an intrinsic property that predisposed them to IL-9 production, we examined CD4 + T cells from the Rorc −/− mice. We found higher expression of IL-9 in ROR-γ − CD4 + T cells ( Supplementary Fig. 3a,b ) and in memory ROR-γ − CD4 + T cells than in the corresponding ROR-γ + CD4 + T cells and memory ROR-γ + CD4 + T cells ( Supplementary Fig. 3c-e) . However, we observed negligible IL-9 expression in naive CD4 + T cells, and crucially, there was no difference in IL-9 expression between ROR-γ + and ROR-γ − naive CD4 + T cells (Supplementary Fig. 3f ), suggesting that naive ROR-γ − T cells have no intrinsic propensity toward IL-9 production ( Supplementary Fig. 3f ). T H 2 and T H 9 cells both secrete IL-9 (refs. 19,20) , and ROR-γ -T H 2 cells had higher IL-9 expression than ROR-γ + T H 2 cells. However, ROR-γ − CD4 + T cells polarized under T H 9 conditions showed comparable IL-9 production to RORγ + T H 9 cells ( Supplementary Fig. 3g,h ).
To determine whether the melanoma growth-inhibitory response in the Rorc −/− ch mice could be attributed to IL-9, we subcutaneously injected melanoma cells into Rorc −/− ch mice as well as Rorc +/+ ch mice. The tumor growth in the Rorc −/− ch mice lagged well behind tumor growth in the Rorc +/+ ch mice (Fig. 3a) . We then treated tumor-bearing Rorc −/− ch mice with neutralizing antibodies to IL-9. The impaired melanoma growth in the Rorc −/− ch mice was substantially, but not (Fig. 3a) . Therefore, we conclude that the melanoma growth inhibition observed in the Rorc −/− ch mice was partially dependent on IL-9.
The role of IL-9 in melanoma immunity in Il23r −/− mice The most strongly downregulated gene in the transcriptional profiling of ROR-γ − CD4 + T cells was Il23r (Fig. 2) . We therefore explored melanoma tumor growth in Il23r −/− mice. We differentiated naive CD4 + T cells from Il23r +/+ and Il23r −/− mice under T H 17 polarizing conditions and re-stimulated these cells using monoclonal antibodies (mAbs) to CD3 and CD28. At 48 h after re-stimulation, we collected the supernatant and measured the amounts of IL-9 and IL-17 (ref. 19) . We found that the IL-23R − CD4 + T cells produced less IL-17A than did the IL-23R + CD4 + T cells (Fig. 3b) . However, the IL23R − CD4 + T cells showed higher IL-9 expression than the IL-23R + CD4 + T cells (Fig. 3b) .
We then injected melanoma cells into Il23r +/+ and Il23r −/− mice and found that melanoma growth was greatly impaired in the Il23r −/− mice. To investigate the role of IL-9 in this tumor growth inhibition, we treated these mice with a neutralizing antibody to IL-9. This neutralization of IL-9 led to enhanced melanoma tumor growth in the Il23r −/− and also in the Il23r +/+ mice (Fig. 3c) , suggesting that the production of IL-9 by tumor-infiltrating lymphocytes (TILs) (Fig. 3d) had a role in suppressing tumor growth. In addition, we isolated and stimulated tumor-site draining lymph node cells (LNCs) from Il23r +/+ and Il23r −/− mice using mAbs specific to CD3 and CD28 for 48 h. We found that IL-23R − T cells secreted more IL-9 in vitro than IL-23R + T cells (Fig. 3e) .
T H 9 cells inhibit melanoma growth As IL-9 is produced mainly by CD4 + T cells 20, 21 , we examined the role of subsets of CD4 + effector T cells in melanoma growth in mice. We generated T H 1, T H 2, T H 9 and T H 17 cells from naive CD4 + T cells of OT-II mice. CD4 + T cells from OT-II mice express a transgenic T cell receptor that recognizes residues 323-339 from ovalbumin in the context of a mouse major histocompatibility (MHC) class II allele expressed in B6 mice (I-A b ). B16F10-ova melanoma cells express the full-length ovalbumin molecule. Before their adoptive transfer into mice, we analyzed the in vitro polarized CD4 + T cells for their cytokine expression ( Supplementary Fig. 4 ). We then transferred the differentiated T H cells and subcutaneously injected B16F10-ova melanoma cells into syngeneic immunocompetent WT mice. The mice treated with the T H 9 cells showed the greatest resistance to melanoma growth compared to mice treated with all other T H cell subsets (Fig. 4a ).
To determine whether T H 9 cells could inhibit the growth of melanoma independently of endogenous T cells, we transferred T H 0 (stimulated and expanded in vitro but not polarized by exogenous cytokines) and T H 9 cells generated from OT-II mice into immunocompromised host mice (Rag1 −/− ). In this setting, the T H 9 cells inhibited the growth of subcutaneous melanoma tumors (Fig. 4b) , and the survival of the T H 9-treated mice was markedly longer than that of the T H 0-treated mice (Fig. 4c) . These data suggest that T H 9 cells are capable of inhibiting melanoma growth, even in the absence of CD8 + T cells. Moreover, blockade of IL-9 accelerated melanoma growth in the T H 9-treated mice, suggesting a partial dependence of this effect on IL-9 ( Fig. 4b ).
To determine whether T H 9 cells could directly kill melanoma cells, we cocultured carboxyfluorescein succinimidyl ester (CFSE) labeled B16F10-ova cells with in vitro-generated T H 0, T H 9 and T H 17 cells from OT-II mice for 24 h. After 24 h of culture, we analyzed apoptosis of tumor cells by staining the B16F10-ova cells (e) IL-9 and IL-17 concentrations as estimated by ELISA in supernatants from tumor draining LNCs. All data are mean ± s.e.m. *P < 0.05, **P < 0.025, ***P < 0.005 by two-tailed Student's t test. Two additional independent experiments (a,c) produced similar results. , with subcutaneous injection of B16F10-ova cells on the same day. n = 6 mice per group. In addition, T H 9-treated mice were also given neutralizing antibodies to IL-9 or isotype control antibodies (b). All data are mean ± s.e.m. *P < 0.05, **P < 0.025, ***P < 0.005 by two-tailed Student's t test. The significant differences in a are compared to the 'no T cell' group. npg with 7-aminoactinomycin D (7-AAD). The T H 9 cells were capable of inducing apoptosis in the melanoma cells, whereas the T H 0 and T H 17 cells were much less effective in this regard ( Supplementary  Fig. 5a ). We then assessed the mechanism of the direct cytotoxicity of the T H 9 cells by measuring a limited profile of effector molecules in T H 9 cells (Supplementary Fig. 5b ). We observed high expression of granzyme-B in the T H 9 cells, and inhibition of granzyme-B expression by a granzyme-B-specific inhibitor (5 μM, ZAAD-CMK, Enzo Life Sciences, USA) diminished the cytotoxic activity of the T H 9 cells against B16F10 melanoma cells (Supplementary Fig. 5c ). To further explore the direct cytotoxic effects of T H 9 cells, we incubated T H 9 cells from OT-II mice with CFSE-labeled B16F10-ova cells or CFSE-labeled EL4 T lymphoma cells for 36 h. The T H 9 cells had dosedependent effects on B16F10-ova tumor cell lysis ( Supplementary  Fig. 6c) . However, the OT-II T H 9 cells did not kill the EL4 cells, which do not express ovalbumin (Supplementary Fig. 6c ).
Treatment with exogenous rIL-9 inhibits tumor growth
To analyze the role of IL-9 signaling in tumor growth, we injected B16F10 melanoma cells into Il9r −/− mice and Il9r +/− mice (control group) and monitored tumor growth. Melanoma tumor growth was accelerated in the Il9r −/− mice compared to growth in the Il9r +/− mice (Fig. 5a) . We next asked whether administration of rIL-9 could protect mice against melanoma growth and progression. Remarkably, treatment of melanoma-bearing WT mice with rIL-9 both impaired melanoma growth (Fig. 5b) and increased the survival of the WT mice compared to the untreated group (data not shown). To determine whether rIL-9 could potentiate the anti-tumor response of a melanoma vaccine, we vaccinated mice with 10 6 irradiated melanoma cells. We then injected live B16F10 melanoma cells 7 d later into all vaccinated mice and divided these mice into two groups. We then treated one group of mice with rIL-9 and another group served as controls (untreated). The rIL-9-treated mice showed markedly less melanoma tumor growth than did the untreated control mice (Supplementary Fig. 6a ).
We then investigated whether rIL-9 could inhibit an unrelated tumor, Lewis lung carcinoma (LLC). The growth of LLC-1 tumor cells was substantially suppressed in rIL-9-treated mice compared to the untreated control mice, showing that the antitumor effect of rIL-9 was not limited to melanoma (Fig. 5c) . However, rIL-9 had no effect on the growth of EL4 lymphomas (data not shown). To rule out the possibility of a direct effect of IL-9 on the tumor cells, we studied IL-9R expression in tumor cells and examined the direct effects of IL-9 on tumor cell growth (Supplementary Fig. 6b-d) . B16F10 cells and LLC-1 cells showed negligible IL-9R expression, and IL-9 did not affect the growth of these cells in vitro, suggesting that the IL-9-mediated antitumor effects on melanoma cells and lung carcinoma cells are indirect. However, we did observe IL-9R expression in EL4 cells (Supplementary Fig. 6c ), and we speculate that a direct survivalpromoting effect of IL-9 may have protected the EL4 cells from the indirect antitumor effects we observed in the B16F10 and LLC-1 cells.
Mast cells are required for the antitumor effect of rIL-9
To investigate the mechanism of IL-9-mediated tumor growth inhibition, we injected B16F10 melanoma cells into Rag1 −/− C57BL/6 mice, which lack T and B cells, and treated the mice with rIL-9. Surprisingly, treatment with rIL-9 inhibited melanoma growth (Fig. 5d) , suggesting npg that the target of the effect of rIL-9 in this setting was not T or B cells. Because IL-9 is also known to promote mast-cell development and function, we injected B16F10 melanoma cells and LLC-1 cells into mast-cell-deficient (Kit W-sh/HNihrJaeBsmJ) mice and then treated the mice with rIL-9 and measured tumor growth (Fig. 5e,f ) . Notably, under these conditions, there was no statistically significant difference in tumor development between the rIL-9-treated and the nontreated control groups. These data suggest that the tumor growth inhibition that is mediated by the administration of rIL-9 depends on the presence of mast cells but not on the presence of T or B cells.
T H 9 cells in human skin, blood and metastatic melanoma We next explored whether T H 9 cells could be identified in humans and, if so, whether they showed a phenotype that was comparable to that of mouse T H 9 cells. Mouse T H 9 cells are defined as a distinct population of CD4 + T cells that produce IL-9 but not IFN-γ, IL-4 or IL-17.
We found that human memory T cells isolated from peripheral blood contained a distinct population of IL-9-producing cells that do not produce IFN-γ, IL-4 or IL-17. We also found T cells with an identical phenotype that were present in even greater abundance in resident T cells (T RM ) isolated from healthy human skin (Fig. 6a,b) . We then examined TILs extracted from metastatic lesions of patients with stage 4 metastatic melanoma (with metastasis to the lung (n = 4), skin (n = 2), adrenal gland (n = 1) or bone (n = 1)) for the presence of IL-9-producing T cells. We observed detectable IL-9-producing T cells in six out of the eight melanoma biopsies; however, T H 9 cells were less abundant in the TILs from these melanoma lesions compared to skin and blood of healthy donors, and the production of IL-9 was demonstrably lower in the T cells from the metastatic melanoma than in memory T cell populations of skin and blood from healthy donors (Fig. 6c) .
DISCUSSION
In this study, we report that mice deficient in pathways related to T H 17 cell development (Rorc −/− and Il23r −/− mice) have substantial resistance to melanoma growth in a manner that is dependent largely on IL-9. In addition, T H 9 cells inhibit tumor growth in an IL-9-dependent manner. Treatment of tumor-bearing mice with exogenous rIL-9 inhibits tumor growth, and this effect requires the presence of mast cells but not T or B cells. We also show that memory T H 9 cells are present in healthy human blood and skin and are also present, albeit at lower amounts, in metastatic melanoma lesions compared with healthy skin and blood. To our knowledge, these findings have not been previously reported.
At the outset of the study, our goal was to assess the role of T H 17 cells in melanoma immunity; thus, we used Rorc −/− ch mice and Il23r −/− mice and found enhanced tumor immunity and delayed tumor growth in both models, suggesting that an intact T H 17 pathway favored tumor growth. It was not clear, however, whether blocking the T H 17 pathway may have favored the emergence of a previously unappreciated antitumor pathway. To explore this possibility, we performed a transcriptional profiling analysis of ROR-γ − CD4 + T cells, which revealed notably higher expression of IL-9 in these cells than in ROR-γ + CD4 + T cells. Little is currently known about the regulation of IL-9. Recent studies have suggested that IL-25 and IL-21 enhance IL-9 expression in mice and humans, respectively 22, 23 . We do not know the precise mechanism by which the absence of ROR-γ promotes IL-9 expression in T cells, although an analysis of the IL-9 promoter did not reveal an ROR-γ binding site (V.K.K., unpublished observations). Our data show greatly impaired IL-23R expression in ROR-γ − CD4 + T cells, as well as higher IL-9 expression in IL-23R − CD4 + T cells than in IL-23R + CD4 + T cells. Therefore, inhibition of signaling by reduced IL-23R expression in ROR-γ − CD4 + T cells might be one of the factors responsible for the higher IL-9 expression.
As IL-9 is a product primarily of CD4 + T cells, we explored the role of T H 9 cells in tumor immunity. Mice treated with adoptively transferred T H 9 cells showed profound resistance to melanoma growth. To our knowledge, this is the first report showing an antitumor effect of T H 9 cells. Previous studies have reported that the adoptive transfer of T H 9 cells can induce colitis and peripheral neuritis in lymphopenic hosts 21 , which is consistent with the key immune effector functions that are mediated by these cells. Similar to previous reports 7, 9, 24 , in our experiments, T H 2 and T H 17 cells, but not T H 0 or T H 1 cells, inhibited melanoma growth. However, the melanoma growth-inhibitory properties of the T H 9 cells were superior to those of the T H 17 cells.
To determine independently whether IL-9 has melanoma growthinhibitory properties, we studied tumor growth in Il9r −/− mice and found that the melanoma tumor growth was reproducibly enhanced in these mice. In addition, treatment with exogenous IL-9 reproducibly suppressed the growth of B16F10 melanoma and LLC-1 cells but not of EL4 cells in WT mice. Next, we examined the IL-9R expression on tumor cells (B16F10 melanoma cells, LLC-1 lewis lung carcinoma cells and EL4 lymphoma cells) and observed expression of IL-9R only on EL4 lymphoma cells. This suggests that the presence of IL-9R in EL4 cells, and the previously reported growth-and survival-promoting properties of IL-9 on T cells, may be responsible for the negligible antitumor effect of IL-9 in this tumor model 25 . Therefore, these data indicate that potential tumor targets of rIL-9 therapy should be selected with care; specifically, lymphomas and other cells known to express receptors for this cytokine may not be appropriate candidates for treatment, although this issue is hypothetical and clearly requires further study. However, taken together, these data are consistent with the idea that IL-9 clearly has an inhibitory effect on solid tumor growth.
Notably, we found no difference between normal wild-type and Rag1 −/− mice in the degree of tumor inhibition that was mediated by exogenous IL-9, suggesting that the beneficial effects of exogenous IL-9 are mediated by other immune cells. Both human 26 and mouse 27 mast cells are well-known targets of IL-9. Recently, mast cells have been implicated as having antitumor activity 28 . Indeed, we observed that treatment with rIL-9 had no measureable inhibitory effect on tumor growth in mast cell-deficient mice, suggesting that these cells have a key, although uncharacterized, role in IL-9-mediated antitumor activity. Studies are currently under way to delineate how IL-9 modulates the antitumor activity (survival and function) of mast cells.
There has been some debate as to whether T H 9 cells are only present in mice, and their relevance to human disease has been questioned. However, we readily detected candidate T H 9 cells in populations of human skin-resident memory T cells, as well as in the memory T cell populations in human peripheral blood mononuclear cells (PBMCs). We also found memory T H 9 cells in metastatic lesions of human patients with melanoma, but at a lower abundance than the steady state of memory T H 9 cells in normal human skin and blood. Our finding of low amounts of T H 9 cells in human metastatic melanoma is noteworthy but should be interpreted with caution. It may be that T H 9 cells are part of the normal human immune response to melanoma, and therefore augmenting their activity or providing additional IL-9 may be therapeutically advantageous in this setting. Further experiments will be necessary to assess the role of IL-9 in human cancer therapy.
The role of IL-9 in melanoma tumor immunity has not been previously studied, to our knowledge. Interestingly, however, single nucleotide polymorphisms in the IL-9 gene were previously found to be npg associated with an increased risk of cutaneous malignant melanoma 29 . The role of IL-9 in tumor immunity in general is not clear, with at least one recent study suggesting that IL-9 promotes regulatory T cell function and inhibits tumor immunity 30 . In our experiments, however, blockade of endogenous IL-9 invariably accelerated tumor development in the melanoma model, and the absence of IL-9 signaling (in Il9r −/− mice) also enhanced melanoma growth. Although our collective results in two different tumor models are consistent with a distinct antitumor effect of IL-9, further studies will determine how generalizable these finding are to tumor growth and immunity.
Our findings suggest that strategies that favor the generation of IL-9-mediated immune responses may have an important role in the treatment of melanoma and other solid tumors. Other γC cytokines, such as IL-2, IL-15 and IL-21 (refs. [31] [32] [33] , have been used in the treatment of human melanoma. In addition, the adoptive therapy of melanoma-antigen-specific T cells, including TILs, has been used extensively in patients with metastatic melanoma 9, [34] [35] [36] [37] [38] . Our data suggest that IL-9 and T H 9 cells may also have role in the treatment of this challenging malignancy.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The microarray data are deposited in Gene Expression Omnibus under accession code GSE38704. 
Note: Supplementary information is available in the online version of the paper.
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